0
Editorials |

Drug Safety in COPD RevisitedDrug Safety in COPD: What Is the Number Needed to Analyze?

Klaus F. Rabe, MD, PhD
Author and Funding Information

From the Christian Albrechts University Kiel, Department of Internal Medicine and Grosshansdorf Clinic.

Correspondence to: Klaus F. Rabe, MD, PhD, Grosshansdorf Clinic, Center of Pulmonary Diseases and Thoracic Surgery, Wöhrendamm 80, 22927 Grosshansdorf, Germany; e-mail: k.f.rabe@kh-grosshansdorf.de


Financial/nonfinancial disclosures: The author has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2012;142(2):271-274. doi:10.1378/chest.12-1395
Text Size: A A A
Published online

Extract

The treatment of COPD worldwide relies on a rather limited selection of pharmacologic principles. Symptomatic benefit and improvement of lung function are afforded by β2-adrenoceptor agonists with largely comparable efficacy and varying durations of action, as well as short- and long-acting anticholinergic drugs, whereas the underlying inflammation in the airways (and systemically) is targeted by (mainly inhaled) corticosteroids and, more recently, orally applied selective phosphodiesterase-4 inhibitors.1,2

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543